STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Clinical trial NCT05721248 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05721248
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Metastatic Breast Cancer HER2-positive Breast Cancer

Start date: 2023-04-19
Primary completion: 2026-06-22
Enrollment: 82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.